BioSpace News Archive

Humacyte, Inc. (Nasdaq: HUMA) today announced financial results for the fourth quarter and year ended December 31, 2023 and highlighted recent corporate accomplishments in advancing the investigational Human Acellular Vessel (HAV) closer to planned U.S. market launch.

OKYO Pharma Limited announced today additional key findings from analyses of the clinical data set from the 240 patient Phase 2, randomized, double-masked, placebo-controlled trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with DED.

Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today provided a corporate update and reported its financial results for the year ended December 31, 2023.

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced promising data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, that is being presented today at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic.

Sensei Biotherapeutics, Inc. today announced that Company management will participate on a panel titled ‘Anti-VISTA Immunotherapies in Clinical Development’ at the 3rd Annual VISTA Symposium.

Robust base business performance and acquisition program combine to deliver double-digit growth across all key metrics, sets optimistic outlook for 2024 Fourth Quarter 2023 Highlights Revenue of $362.2 million, an increase of 9.4% over the fourth quarter of 2022, with Same Practice Revenue Growth (“SPRG”)¹ of 6.7%. Adjusted EBITDA¹ of $65.8 million, an increase of 8.6% compared to the same period in 2022; Adjusted EBITDA margin¹ of 18.2%. Adjusted Net Income¹

Daxor Corporation announces an investor call to be held on Monday, March 25, 2024, at 4:00 p.m. ET.

Belite Bio, Inc today announces its submission to the Pharmaceuticals and Medical Devices Agency (PMDA) to initiate a clinical trial of Tinlarebant in adolescent STGD1 in Japan (“DRAGON II”).

Recce Pharmaceuticals Ltd today announced it has been issued a trademark registration for RECCE ® from the Canadian Intellectual Property Office, strengthening its global intellectual property (IP) portfolio.

Sangamo Therapeutics, Inc. today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of an aggregate of 24,761,905 shares of its common stock.